All In Biotech

Drug Trial Radar · NCT01309243

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

A Phase 3B, Randomized, Open-label Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Last checked: Nov 20, 2026Latest source record: Feb 25, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 799 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

799

Actual

Start

Feb 2011

Primary completion

Sep 2012

Study completion Feb 2014

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Mar 7, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study was to evaluate the safety and efficacy of the emtricitabine (FTC)/rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF) single-tablet regimen (STR) compared with the efavirenz (EFV)/FTC/TDF STR in HIV-1 infected adults who had not previously received treatment with antiretroviral medications. Participants were randomized in a 1:1 ratio to receive one of the study treatments. Randomization was stratified by HIV-1 RNA level (≤ 100,000 copies/mL or \> 100,000 copies/mL) at screening. A treatment duration of 96 weeks was planned, with the option for subjects in FTC/RPV/TDF STR arm to receive treatment following the Week 96 visit until FTC/RPV/TDF STR is commercially available or until Gilead Sciences elects to terminate development in that country.

Conditions

  • HIV-1 Infection

Interventions

  • FTC/RPV/TDFDrug

    Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal

  • EFV/FTC/TDFDrug

    Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48Time frame: Week 48

Locations

151 sites in 14 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Spectrum Medical Group

    Phoenix, Arizona

  • AHF Research Center

    Beverly Hills, California

  • Kaiser Permanente Medical Center

    Hayward, California

  • Living Hope Education and Research Consultants

    Long Beach, California

  • Kaiser Permanente Medical Center

    Los Angeles, California

  • Jeffrey Goodman Special Care Clinic/Los Angeles Gay and Lesbian Center

    Los Angeles, California

  • Lightsource Medical

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Oasis Clinic

    Los Angeles, California

  • Anthony Mills MD Inc

    Los Angeles, California

  • Orange Coast Medical Group

    Newport Beach, California

  • East Bay AIDS Center

    Oakland, California

  • Stanford University

    Palo Alto, California

  • University of California, Davis

    Sacramento, California

  • Kaiser Permanente Medical Group

    Sacramento, California

  • La Playa Medical Group and Clinical Research

    San Diego, California

  • Metropolis Medical/Dr.Fritz

    San Francisco, California

  • Kaiser Permanente Medical Center, San Francisco

    San Francisco, California

  • Apex Research LLC

    Denver, Colorado

  • Dupont Circle Physician's Group

    Washington D.C., District of Columbia

  • Whitman-Walker Clinic

    Washington D.C., District of Columbia

  • Capital Medical Associates, PC

    Washington D.C., District of Columbia

  • Medical Faculty Associates

    Washington D.C., District of Columbia

  • Broward General Medical Center

    Fort Lauderdale, Florida

  • Gary J. Richmond, M.D., P.A.

    Fort Lauderdale, Florida

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • The Kinder Medical Group

    Miami, Florida

  • Wohlfeiler, Piperato and Associates, LLC

    Miami Beach, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • Valuhealthmd,Llc / Idocf

    Orlando, Florida

  • Infectious Disease Associates of NW FL

    Pensacola, Florida

  • AHF Health Positive - Tampa Bay

    Safety Harbor, Florida

  • St. Joseph's Hospital d/b/a Comprehensive Research Institute

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • AIDS Research Consortium of Atlanta

    Atlanta, Georgia

  • Atlanta ID Group

    Atlanta, Georgia

  • Infectious Disease Specialists of America

    Decatur, Georgia

  • Mercer University School of Medicine

    Macon, Georgia

  • Clint Spencer Clinic

    Honolulu, Hawaii

Showing 40 of 151 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.